Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 15;14(4):363–371. doi: 10.1007/s13340-023-00638-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Japan Diabetes Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 2 — Usage of diabetes medication with proven CV benefit stratified by CVD groups among CAPTURE study participants in Japan. ^aASCVD is a subgroup of CVD. ^bSubcutaneous administration: once-weekly dulaglutide, once-daily liraglutide, once-weekly semaglutide. ^cOral administration (all once daily): empagliflozin, canagliflozin, dapagliflozin. ASCVD atherosclerotic cardiovascular disease, CVD cardiovascular disease, GLP-1 RA glucagon-like peptide-1 receptor agonist, SGLT-2i sodium-glucose cotransporter-2 inhibitor